Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.
-
Adult
-
Aged
-
Aged, 80 and over
-
Anemia
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antibodies, Neoplasm
-
Antineoplastic Combined Chemotherapy Protocols
-
Disease-Free Survival
-
Drug Administration Schedule
-
Fatigue
-
Female
-
Humans
-
Injections, Subcutaneous
-
Leukemia, Lymphocytic, Chronic, B-Cell
-
Male
-
Middle Aged
-
Nausea
-
Neoplasm, Residual
-
Remission Induction
-
Treatment Outcome
-
Vidarabine
-
Young Adult